Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To investigate whether intranasal oxytocin (24 IU) treatment can influence prosocial learning behavior in males.
In a double-blind, within-subject, placebo controlled design, investigators plan to investigate the effect of oxytocin treatment on prosocial learning. Before the self-administration, participants need to finish several questionnaires including IRI, AAS, BASBIS, SPSRQ, SES, PTM, STAI, BDI, ASQ and PNAS. They would finish the PANAS again before the scanning.
Participants are informed that they perform the reward learning task either for themselves, another (unknown) person or no one (control). In the probabilistc reward learning task, associations with two stimuli with different reward probabilities are learned via monetary feedback (reward ï¿¥1 or no reward ï¿¥0). After the experiment, participants need to finish the PANAS.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| male oxytocin group | Experimental | male subjects with oxytocin treatment |
|
| male placebo group | Placebo Comparator | male subjects with placebo treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oxytocin | Drug | intranasal administration of oxytocin (24 IU) |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Neural processing during feedback based on prosocial learning assessed by fMRI scanner | fMRI BOLD indices of neural processing learning related brain regions will be compared between the treatment administrations. | 1 hour |
| Measure | Description | Time Frame |
|---|---|---|
| Behavioral learning performance measured by E-prime | Learning performance will be compared between the treatment administrations by calculating the accuracy of learning. | 1 hour |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Keith Kendrick, Dr. | University of Electronic Science and Technology of China | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| School of Life Science and Technology, University of Electronic Science and Technology of China | Chengdu | Sichuan | China |
Not provided
| ID | Term |
|---|---|
| D010121 | Oxytocin |
| ID | Term |
|---|---|
| D010909 | Pituitary Hormones, Posterior |
| D010907 | Pituitary Hormones |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
intranasal administration of placebo (24 IU) |
|
| D006730 |
| Hormones, Hormone Substitutes, and Hormone Antagonists |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |